ARVN vs. RYTM, DYN, SNDX, MORF, AKRO, ROIV, ELAN, LEGN, ASND, and CERE
Should you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include Rhythm Pharmaceuticals (RYTM), Dyne Therapeutics (DYN), Syndax Pharmaceuticals (SNDX), Morphic (MORF), Akero Therapeutics (AKRO), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Legend Biotech (LEGN), Ascendis Pharma A/S (ASND), and Cerevel Therapeutics (CERE). These companies are all part of the "pharmaceutical preparations" industry.
Arvinas (NASDAQ:ARVN) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, risk, earnings, media sentiment, dividends and valuation.
In the previous week, Arvinas and Arvinas both had 5 articles in the media. Arvinas' average media sentiment score of 1.72 beat Rhythm Pharmaceuticals' score of 0.66 indicating that Arvinas is being referred to more favorably in the media.
95.2% of Arvinas shares are held by institutional investors. 5.2% of Arvinas shares are held by company insiders. Comparatively, 5.6% of Rhythm Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Arvinas has a beta of 1.95, meaning that its stock price is 95% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 1.94, meaning that its stock price is 94% more volatile than the S&P 500.
Arvinas presently has a consensus price target of $61.13, suggesting a potential upside of 84.47%. Rhythm Pharmaceuticals has a consensus price target of $54.33, suggesting a potential upside of 52.28%. Given Arvinas' stronger consensus rating and higher probable upside, equities research analysts clearly believe Arvinas is more favorable than Rhythm Pharmaceuticals.
Rhythm Pharmaceuticals has lower revenue, but higher earnings than Arvinas. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.
Rhythm Pharmaceuticals received 104 more outperform votes than Arvinas when rated by MarketBeat users. Likewise, 65.71% of users gave Rhythm Pharmaceuticals an outperform vote while only 65.40% of users gave Arvinas an outperform vote.
Arvinas has a net margin of -185.09% compared to Rhythm Pharmaceuticals' net margin of -297.91%. Arvinas' return on equity of -64.79% beat Rhythm Pharmaceuticals' return on equity.
Summary
Arvinas beats Rhythm Pharmaceuticals on 12 of the 17 factors compared between the two stocks.
Get Arvinas News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools